Akero Therapeutics, Inc.
AKRO
$54.59
-$0.11-0.19%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.29% | 2.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.58% | -0.01% | |||
| Operating Income | -11.58% | 0.01% | |||
| Income Before Tax | -15.69% | 0.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.69% | 0.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.69% | 0.31% | |||
| EBIT | -11.58% | 0.01% | |||
| EBITDA | -11.58% | 0.01% | |||
| EPS Basic | -15.29% | 4.06% | |||
| Normalized Basic EPS | -13.09% | 4.06% | |||
| EPS Diluted | -15.29% | 4.06% | |||
| Normalized Diluted EPS | -13.09% | 4.06% | |||
| Average Basic Shares Outstanding | 0.35% | 3.90% | |||
| Average Diluted Shares Outstanding | 0.35% | 3.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||